Feprazone compared with indomethacin in the management of rheumatoid arthritis.
A double-blind cross-over trial of feprazone 450 mg daily and indomethacin 75 mg daily was carried out in fourteen patients with rheumatoid arthritis. The analgesic and anti-inflammatory activity was indistinguishable from that of indomethacin under the conditions of the trial. Seven patients expressed a preference for feprazone and four for indomethacin. Feprazone appeared to be well tolerated and free from serious side-effects. These results suggest that feprazone will be a useful drug in the management of rheumatoid arthritis.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005260:Female; D011298:Feprazone / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D011298:Feprazone; D010653:Phenylbutazone; D007213:Indomethacin